Table 2. Risk factors for early death (development data set).
Univariate analysis
|
Multivariate analysis
|
|||||
---|---|---|---|---|---|---|
Parameters | RR (eβ) | 95% CI | P-value | RR (eβ) | 95% CI | P-value |
Age | ||||||
40–49 vs <40 | 1.32 | 0.87–2.00 | 0.1816 | |||
50–59 vs <40 | 1.41 | 0.95–2.08 | 0.8450 | |||
⩾60 vs <40 | 1.77 | 1.21–4.61 | 0.0030 | |||
Gender: female vs male | 1.04 | 0.80–1.35 | 0.7586 | |||
Performance status | ||||||
1 vs 0 | 3.04 | 2.11–4.36 | <.0001 | 3.83 | 2.06–7.12 | <.0001 |
2–3 vs 0 | 10.00 | 6.62–14.82 | <.0001 | 12.00 | 5.53–26.06 | <.0001 |
Interval a | ||||||
Q2 vs Q1 | 0.80 | 0.55–1.17 | 0.2618 | |||
Q3 vs Q1 | 0.87 | 0.63–1.20 | 0.4528 | |||
Q4 vs Q1 | 0.41 | 0.27–0.61 | <.0001 | |||
Histological subtype | ||||||
MFH vs leiomyo | 1.32 | 0.82–2.10 | 0.244 | |||
Fibro vs leiomyo | 0.59 | 0.21–1.68 | 0.325 | |||
Lipo vs leiomyo | 0.72 | 0.38–1.33 | 0.314 | |||
Angio vs leiomyo | 0.94 | 0.36–2.44 | 0.899 | |||
Syno vs leiomyo | 0.23 | 0.08–0.65 | 0.005 | |||
MPNST vs leiomyo | 0.48 | 0.21–1.07 | 0.074 | |||
Rhabdo vs leiomyo | 0.95 | 0.59–1.15 | 0.818 | |||
Unclassified vs leiomyo | 1.20 | 0.65–2.21 | 0.558 | |||
Other vs leiomyo | 0.91 | 0.40–2.06 | 0.826 | |||
Grade | ||||||
II vs | 1.39 | 0.77–2.95 | 0.2749 | |||
III v I | 1.99 | 1.13–3.49 | 0.0164 | |||
Primary site | ||||||
Head/neck vs limb | 1.88 | 0.88–4.00 | 0.1029 | |||
Trunk vs limb | 1.54 | 1.03–2.30 | 0.0338 | |||
Viscera vs limb | 1.61 | 1.06–2.45 | 0.0249 | |||
Lung met.: yes vs no | 1.07 | 0.83–1.40 | 0.5706 | |||
Liver met.: yes vs no | 1.57 | 1.19–2.14 | 0.0041 | 2.377 | 1.39–4.05 | 0.0014 |
Bone met.: yes vs no | 1.13 | 0.73–1.74 | 0.5690 | |||
Other met.: yes vs no | 1.50 | 1.12–2.01 | 0.0061 | 2.002 | 1.22–3.27 | 0.0055 |
Abbreviations: CI=confidence interval; RR=relative risk; MHF=malignant histiocytofibroma; MPNST=malignant peripheral nerve sheath tumour; met.=metastasis.
Q1: 0–60 days; Q2: 61–180 days; Q3: 181–540 days; and Q4:>540 days.